2Jemal A, Bray F, Center MM, et al. Global cancer statis- tics[J]. CA Cancer J Clin, 2011, 61(2): 134.
3Gronberg H. Prostate cancer epidemiology[J]. Lancet, 2003, 361(7) : 859-864.
4Jemal A, Siegel R, Xu J, et al. Cancer statistics[J]. CA Can- cerJ Clin, 2010, 60(5): 277-300.
5Bannuru RR, Dvorak T, Obadan N, et al. Comparative e- valuation of radiation treatments for clinically localized prostate cancer: an updated systematic review[J]. Ann Intern Med, 2011, 155(3): 171-178.
6. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era[J]. Int J Radiat Oncol Biol Phys, 2000, 48(2): 507-512.
7Hanks GE, Leibe SA, Krall JM, et al. Patterns of care stud- ies: dose-response observation s for local control of adeno- carcinoma of the prostate[J]. Int J Radiat Oncol Biol Phys, 1984, 10(2): 401-409.
8Michalski JM, WinterK, Purdy JA, et al. Toxicity after th- ree-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV [J]. Int J Radiat Oncol Biol Phys, 2004, 58(3) : 735-742.
9Pilepich MV, Winter K, Lawton CA, et al. Androgen sup- pression adjuvant to definitive radiotherapy in prostate carci- noma long-term results of RTOG 85-3 1[J]. Int J Radiat Oncol Bio Phys, 2005, 61(5): 1285-1290.
10Kupelian P, Kuban D, Thames H, et al. Improved biochem- ical relapse-free survival with increased external radiation doses in patients with localized prostate cancer:the com- bined experience of nine institutions in patients treated in 1994 and 1995 [J]. Int J Radiat Oncol Biol Phys, 2005, 61 (2): 415-419.
